CentralReach vs Rethink — how ABA agencies actually choose

CentralReach and Rethink are both established ABA platforms aimed at different buyers: CentralReach at agencies wanting one system for the whole revenue cycle, Rethink at organizations that value its clinical content library and its payer-side relationships. Neither publishes a rate card, so both evaluations start with a quote.

The two are aimed at different buyers

Agencies short-list these two together because both are mature, both are sold to multi-site ABA organizations, and both quote rather than publish. The comparison is harder than it should be for exactly that reason: you cannot line up the prices, so the decision has to be made on fit.

The most useful framing is what each company is organized around. CentralReach sells breadth — one platform intended to carry an agency from intake through claim submission and remittance, with a decade of accumulated depth aimed at large organizations. Rethink’s centre of gravity is its clinical content and its relationships on the payer and employer side, which is a different proposition from a records system with billing attached.

Agencies that want one vendor to own the whole revenue cycle tend to land on CentralReach. Agencies that value the clinical library, or that arrive through a health-plan or employer channel, tend to land on Rethink.

What to compare them on

Structure for your own evaluation. Cells are deliberately unfilled pending dated public sources — see the note above.

	MegAligna	CentralReach	Rethink
Published pricing	Yes	No	No
Priced per active clinical seat, clients free	Yes	No	No
Direct electronic claim submission ³	No	Yes	Partial

³ The row that most often decides this comparison, and the row where we lose. Agencies that submit their own claims electronically should not be evaluating us at all.

The questions worth asking both vendors are the same ones: what the total is at your actual headcount rather than at a headline rate, what happens to session data when a technician loses connectivity mid-session, how long a support response takes in practice, and what a full export of your own data looks like on the day you leave.

That last one is worth pressing on with any quote-only vendor.

Where MegAligna fits, and where it does not

If you are comparing these two, you are probably an agency of a size where both make sense — and in that case the honest answer is that a newer product is a different kind of bet, not a cheaper version of the same one.

What is genuinely different here: prices are published, billing is per active clinical seat with clients never charged for, and session capture survives a dropped connection rather than losing in-progress data. What is genuinely missing: claims are not transmitted to payers. Finished charges go to your biller. An agency that submits electronically today would be giving that up.

Three situations make staying put the right call, and they apply to both incumbents: you submit your own claims, you depend on a capability built over a decade that we have not built, or you are mid-audit.

If the shortlist is wider than these two, Office Puzzle vs CentralReach and Noteable vs CentralReach cover the other head-to-heads agencies run at this stage. For the money question specifically, what a CentralReach quote depends on sets out the variables that move it.

Common questions

Which one is cheaper?

Neither publishes a rate card, so any figure you find for either is a third-party estimate. Both evaluations start with a quote against your own headcount and client count, and the two vendors do not necessarily price on the same unit — which is what makes the comparison hard rather than expensive.

Is CentralReach private-equity owned?

No. CentralReach was acquired by Roper Technologies in March 2025. Roper is a strategic acquirer that holds businesses long-term, which is a materially different ownership model from private equity, and the distinction matters if your concern is what happens to the product roadmap.

Do either of them publish pricing?

Neither does. Among ABA platforms, Motivity and Raven Health do publish per-learner rates, and we publish ours, so a shortlist that includes at least one published-price vendor gives you a reference point the quotes can be read against.

Can we run a new system alongside the old one?

For an agency this size a parallel period is the evaluation that shows your practice rather than a demo — but it puts real client records in the new system, so it starts only once a business associate agreement covers that system. Ask every vendor on the shortlist for theirs before planning one. Until then, a trial on test clients shows the workflow, and because MegAligna charges per active clinical seat, a later pilot costs what one team costs rather than what the agency costs.

Put a third option on the shortlist

14 days, no card required. Use made-up patients while you evaluate — real patient information waits until a business associate agreement is in place.

Start a 14-day free trial